JP2021530218A5 - - Google Patents
Info
- Publication number
- JP2021530218A5 JP2021530218A5 JP2021500538A JP2021500538A JP2021530218A5 JP 2021530218 A5 JP2021530218 A5 JP 2021530218A5 JP 2021500538 A JP2021500538 A JP 2021500538A JP 2021500538 A JP2021500538 A JP 2021500538A JP 2021530218 A5 JP2021530218 A5 JP 2021530218A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- aav
- capsid protein
- delivery
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024092463A JP7897894B2 (ja) | 2018-07-11 | 2024-06-06 | 血液脳関門を超える薬剤の送達のための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696422P | 2018-07-11 | 2018-07-11 | |
| US62/696,422 | 2018-07-11 | ||
| PCT/US2019/041386 WO2020014471A1 (en) | 2018-07-11 | 2019-07-11 | Methods and compositions for delivery of agents across the blood-brain barrier |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024092463A Division JP7897894B2 (ja) | 2018-07-11 | 2024-06-06 | 血液脳関門を超える薬剤の送達のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021530218A JP2021530218A (ja) | 2021-11-11 |
| JP2021530218A5 true JP2021530218A5 (cg-RX-API-DMAC10.html) | 2022-07-19 |
Family
ID=69142796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500538A Withdrawn JP2021530218A (ja) | 2018-07-11 | 2019-07-11 | 血液脳関門を超える薬剤の送達のための方法および組成物 |
| JP2024092463A Active JP7897894B2 (ja) | 2018-07-11 | 2024-06-06 | 血液脳関門を超える薬剤の送達のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024092463A Active JP7897894B2 (ja) | 2018-07-11 | 2024-06-06 | 血液脳関門を超える薬剤の送達のための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US12398181B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3820885A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2021530218A (cg-RX-API-DMAC10.html) |
| CN (2) | CN112703198B (cg-RX-API-DMAC10.html) |
| CA (1) | CA3105381A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020014471A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019200016A1 (en) | 2018-04-10 | 2019-10-17 | President And Fellows Of Harvard College | Aav vectors encoding clarin-1 or gjb2 and uses thereof |
| JP2021530218A (ja) * | 2018-07-11 | 2021-11-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 血液脳関門を超える薬剤の送達のための方法および組成物 |
| CN113166208B (zh) | 2018-10-02 | 2024-11-22 | 沃雅戈治疗公司 | 重新定向aav衣壳的嗜性 |
| AU2020214831B2 (en) * | 2019-01-30 | 2025-09-25 | The Broad Institute, Inc. | Systems for evolved adeno-associated viruses (AAVs) for targeted delivery |
| CN115023242B (zh) * | 2019-11-22 | 2025-03-14 | 费城儿童医院 | 腺相关病毒载体变体 |
| CA3167290A1 (en) | 2020-01-10 | 2021-07-15 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer |
| FI4103214T3 (fi) | 2020-02-13 | 2026-07-03 | Tenaya Therapeutics Inc | Geeniterapian vektorit sydänsairauden hoitoon |
| AU2021265832A1 (en) | 2020-04-29 | 2022-11-24 | The Broad Institute, Inc. | Machine learning accelerated protein engineering through fitness prediction |
| US12630842B2 (en) * | 2020-05-13 | 2026-05-19 | Voyager Therapeutics, Inc. | Redirection of tropism of AAV capsids |
| EP4199972A4 (en) * | 2020-08-21 | 2025-01-15 | Capsida, Inc. | ADENO-ASSOCIATED VIRUS COMPOSITIONS WITH PREFERRED EXPRESSION LEVELS |
| US12129287B2 (en) | 2020-09-14 | 2024-10-29 | President And Fellows Of Harvard College | Recombinant adeno associated virus encoding clarin-1 and uses thereof |
| CN112194706B (zh) * | 2020-09-30 | 2022-03-08 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| AU2022266615A1 (en) * | 2021-04-27 | 2023-11-09 | The General Hospital Corporation | Aav capsids and uses thereof |
| WO2022272240A2 (en) * | 2021-06-21 | 2022-12-29 | The Brigham And Women’S Hospital, Inc. | Adeno-associated viral (aav) vectors for tissue-targeted expression of therapeutic genes |
| KR102934033B1 (ko) * | 2021-10-01 | 2026-03-06 | 서울대학교산학협력단 | 혈액 뇌장벽 투과용 펩타이드 및 이의 용도 |
| KR20240095539A (ko) | 2021-10-08 | 2024-06-25 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 변이체 및 이의 사용 방법 |
| EP4426716A1 (en) | 2021-11-02 | 2024-09-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| CN114606264B (zh) * | 2022-03-22 | 2025-08-26 | 三峡大学 | 一种用于神经系统药物递送的aav病毒载体 |
| WO2023240236A1 (en) * | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| JP2026509271A (ja) | 2023-03-10 | 2026-03-17 | ダイノ セラピューティクス，インコーポレーテッド | カプシドポリペプチドおよびその使用方法 |
| WO2024229777A1 (zh) * | 2023-05-11 | 2024-11-14 | 深圳先进技术研究院 | 一种aav载体及其应用 |
| WO2024249810A2 (en) * | 2023-06-02 | 2024-12-05 | The Brigham And Women's Hospital, Inc. | Combinatory use of adeno-associated viruses and focused ultrasound for overcoming the blood-brain barrier |
| TW202515898A (zh) | 2023-06-30 | 2025-04-16 | 日商武田藥品工業股份有限公司 | Ｈｔｔ抑制物及其用途 |
| CN116808231B (zh) * | 2023-07-07 | 2024-03-26 | 中国药科大学 | 一种细胞穿膜肽偶联舒必利前药体系以及制备方法和应用 |
| CN117964715B (zh) * | 2023-07-21 | 2025-01-24 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| KR20260082361A (ko) | 2023-08-31 | 2026-06-04 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 폴리펩타이드 및 이의 사용 방법 |
| WO2025076091A1 (en) * | 2023-10-03 | 2025-04-10 | Brave Bio, Inc. | Cd20 antibody aav vectors and methods of use thereof |
| TW202535908A (zh) * | 2023-11-02 | 2025-09-16 | 美商渤健麻塞諸塞州股份有限公司 | 中樞神經系統靶向之ａａｖ衣殼之重定向 |
| TW202545971A (zh) | 2024-02-08 | 2025-12-01 | 美商戴諾治療公司 | 殼體多肽及其使用方法 |
| WO2025231400A1 (en) | 2024-05-03 | 2025-11-06 | Sangamo Therapeutics, Inc. | Synthetic transcription factors and methods of making and using thereof |
| WO2026064442A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026122963A1 (en) | 2024-12-06 | 2026-06-11 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| CN120230754B (zh) * | 2025-03-28 | 2026-03-17 | 贵州医科大学 | 一种基因、融合蛋白、重组载体、重组细胞、脑靶向外泌体及其应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US6054312A (en) | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
| DE60035057T2 (de) | 1999-10-04 | 2008-01-31 | Novartis Vaccines and Diagnostics, Inc., Emeryville | CD40 Antagonist zur Behandlung von Psoriasis |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| CA2658221C (en) | 2001-04-27 | 2012-11-27 | Kyowa Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| EP1707627B1 (en) | 2003-12-25 | 2012-11-14 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic anti-CD40 antibody mutant |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| SMP200800064B (it) | 2006-04-21 | 2009-11-06 | Novartis Ag | Composizioni farmaceutiche di anticorpi anti-cd40 antagonista |
| CA2693712C (en) | 2007-07-14 | 2018-05-29 | The University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| WO2010129023A2 (en) | 2009-04-28 | 2010-11-11 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
| EP2796467B1 (en) | 2010-03-31 | 2018-03-28 | Boehringer Ingelheim International GmbH | Anti-CD40 antibodies |
| DK2561073T3 (en) * | 2010-04-23 | 2016-12-12 | Univ Massachusetts | Aav vectors targeted to central nervous system and methods of use thereof |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| EP3702460A1 (en) | 2010-11-12 | 2020-09-02 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| AU2011349464B2 (en) | 2010-12-20 | 2016-07-07 | The General Hospital Corporation | Polycomb-associated non-coding RNAS |
| ES2734076T3 (es) | 2011-02-17 | 2019-12-04 | Kyowa Hakko Kirin Co Ltd | Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada |
| DK3693025T3 (da) | 2011-04-22 | 2022-01-10 | Univ California | Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf |
| KR102037432B1 (ko) | 2011-04-29 | 2019-11-27 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| PL2900686T3 (pl) | 2012-09-28 | 2021-01-25 | The University Of North Carolina At Chapel Hill | Wektory aav ukierunkowane na oligodendrocyty |
| AU2013332061A1 (en) | 2012-10-17 | 2015-05-07 | Fondazione Telethon | Gene therapy for glycogen storage diseases |
| CA2888763A1 (en) | 2012-10-30 | 2014-05-08 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| US10253099B2 (en) * | 2012-12-05 | 2019-04-09 | Ruprecht-Karls-Universität Heidelberg | Conjugates of proteins and multivalent cell-penetrating peptides and their uses |
| KR102298579B1 (ko) | 2013-05-21 | 2021-09-07 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 캡시드-변형된 raav3 벡터 조성물, 및 인간 간암의 유전자 요법에서의 용도 |
| AU2014276440A1 (en) | 2013-06-03 | 2015-11-05 | Novartis Ag | Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor |
| EP3564379A1 (en) * | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| WO2015060722A1 (en) | 2013-10-24 | 2015-04-30 | Uniqure Ip B.V. | Aav-5 pseudotyped vector for gene therapy for neurological diseases |
| US11053291B2 (en) * | 2014-02-19 | 2021-07-06 | University Of Florida Research Foundation, Incorporated | Delivery of Nrf2 as therapy for protection against reactive oxygen species |
| EP4050020A1 (en) | 2014-03-11 | 2022-08-31 | University of Florida Research Foundation, Inc. | Aav-expressed m013 protein as an anti-inflammatroy therapeutic for use in a method of treating inflammatory ocular disease |
| US10577627B2 (en) * | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| CN106604933B (zh) | 2014-07-11 | 2021-08-10 | 文塔纳医疗系统公司 | 抗pd-l1抗体及其诊断用途 |
| US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| WO2016138525A1 (en) * | 2015-02-27 | 2016-09-01 | University Of Washington | Polypeptide assemblies and methods for the production thereof |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| CA3172682A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| CN104965364B (zh) | 2015-07-14 | 2018-03-30 | 武汉华星光电技术有限公司 | 阵列基板及驱动阵列基板的方法 |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| EP3373979A1 (en) | 2015-11-12 | 2018-09-19 | Pfizer Inc | Tissue-specific genome engineering using crispr-cas9 |
| AU2016366549B2 (en) * | 2015-12-11 | 2022-11-10 | California Institute Of Technology | Targeting peptides for directing adeno-associated viruses (AAVs) |
| CN106939047B (zh) | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| CA3011939A1 (en) | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
| EP3583220A4 (en) | 2017-02-15 | 2021-07-07 | The University of North Carolina at Chapel Hill | PROCEDURES AND COMPOSITIONS FOR GENERAL TRANSFER IN THE VASCULAR SYSTEM |
| WO2019012176A1 (en) | 2017-07-11 | 2019-01-17 | Outotec (Finland) Oy | WATERING APPARATUS |
| US11512327B2 (en) | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| JP7403165B2 (ja) | 2017-12-19 | 2023-12-22 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 血液脳関門を通過してウイルスベクターを送達するための方法および組成物 |
| WO2019222329A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| US20210207167A1 (en) | 2018-05-16 | 2021-07-08 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
| SG11202012203PA (en) | 2018-06-27 | 2021-01-28 | Precigen Inc | In vivo controlled combination therapy for treatment of cancer |
| AU2019299555A1 (en) | 2018-07-04 | 2021-02-25 | Cytoimmune Therapeutics, Inc. | Compositions and methods for immunotherapy targeting FLT3, PD-1, and/or PD-L1 |
| JP2021530218A (ja) | 2018-07-11 | 2021-11-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 血液脳関門を超える薬剤の送達のための方法および組成物 |
| EP3830107A2 (en) | 2018-08-03 | 2021-06-09 | Voyager Therapeutics, Inc. | Aav variants with enhanced tropism |
| US11149256B2 (en) | 2018-09-26 | 2021-10-19 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
| CN113166208B (zh) | 2018-10-02 | 2024-11-22 | 沃雅戈治疗公司 | 重新定向aav衣壳的嗜性 |
| US20210371470A1 (en) | 2018-10-12 | 2021-12-02 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| AU2020214831B2 (en) | 2019-01-30 | 2025-09-25 | The Broad Institute, Inc. | Systems for evolved adeno-associated viruses (AAVs) for targeted delivery |
| SG11202111249YA (en) | 2019-04-11 | 2021-11-29 | California Inst Of Techn | Virus compositions with enhanced specificity in the brain |
| US20230075314A1 (en) | 2019-04-29 | 2023-03-09 | Voyager Therapeutics, Inc. | VECTORIZED ANTIBODIES (vAb) AND USES THEREOF |
| WO2021025995A1 (en) | 2019-08-02 | 2021-02-11 | Voyager Therapeutics, Inc. | Aav variants with enhanced tropism |
| CA3167290A1 (en) | 2020-01-10 | 2021-07-15 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer |
| WO2022272240A2 (en) | 2021-06-21 | 2022-12-29 | The Brigham And Women’S Hospital, Inc. | Adeno-associated viral (aav) vectors for tissue-targeted expression of therapeutic genes |
-
2019
- 2019-07-11 JP JP2021500538A patent/JP2021530218A/ja not_active Withdrawn
- 2019-07-11 CA CA3105381A patent/CA3105381A1/en active Pending
- 2019-07-11 CN CN201980059342.1A patent/CN112703198B/zh active Active
- 2019-07-11 WO PCT/US2019/041386 patent/WO2020014471A1/en not_active Ceased
- 2019-07-11 EP EP19833958.2A patent/EP3820885A4/en active Pending
- 2019-07-11 CN CN202510648887.3A patent/CN120843603A/zh active Pending
- 2019-07-11 US US17/258,846 patent/US12398181B2/en active Active
-
2021
- 2021-12-02 US US17/457,337 patent/US11518787B2/en active Active
-
2022
- 2022-10-21 US US18/048,716 patent/US20230077490A1/en active Pending
-
2024
- 2024-06-06 JP JP2024092463A patent/JP7897894B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022527917A5 (cg-RX-API-DMAC10.html) | ||
| CN112703198B (zh) | 用于跨血脑屏障递送试剂的方法和组合物 | |
| JP7374119B2 (ja) | 減少した肝臓向性を有するＡＡＶ９とＡＡＶｒｈ７４とのハイブリッド組換えアデノ随伴ウイルス血清型 | |
| JP7004328B2 (ja) | 高形質導入効率ｒＡＡＶベクター、組成物、および使用方法 | |
| US20210269487A1 (en) | Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof | |
| RU2018120736A (ru) | Нацеливающие пептиды для направленной доставки аденоассоциированных вирусов (aav) | |
| CN113966399A (zh) | 用于靶向基因疗法的腺相关病毒组合物 | |
| RU2017121593A (ru) | Векторы aav, нацеленные на центральную нервную систему | |
| JP2023528580A (ja) | 筋肉及び中枢神経系障害の遺伝子治療のための合成ａａｖカプシドの使用 | |
| WO2023060269A4 (en) | Recombinant adeno-associated viruses for targeted delivery | |
| US11421219B2 (en) | Methods and compositions for treating Leber congenital amaurosis | |
| TW202523846A (zh) | 用於治療與共濟蛋白(frataxin)不足有關之疾病之組合物及方法 | |
| WO2025038805A1 (en) | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency | |
| CA3197316A1 (en) | Neurod1 and dlx2 vector | |
| JP2023510784A5 (cg-RX-API-DMAC10.html) | ||
| IL294608A (en) | Methods and compositions for administering immunotherapy agents across the blood-brain barrier for the treatment of brain cancer | |
| JP7811409B2 (ja) | 筋ジストロフィー治療のための遺伝子導入発現カセット | |
| KR20260045798A (ko) | 증가된 뇌 풍부화를 갖는 아데노-연관 바이러스 조성물 | |
| JP2023543360A (ja) | Ｄｌｘ２ベクター | |
| ammatory Macrophage | Plenary Abstract Session | |
| WO2024229028A2 (en) | Novel regulatory cassettes for specific expression of genes in muscle stem cells | |
| WO2025048709A1 (en) | Composition and methods for identification of novel aav variants for differentiated gene delivery to cardiomyoctes and/or skeletal myofibers | |
| Wein et al. | A single neonatal injection of an AAV9. U7snRNA virus mediating skipping of dmd exon 2 allows dystrophin expression preventing apparition of pathologic features in the Dup2 mouse one year post injection | |
| CN116761812A (zh) | Neurod1和dlx2载体 | |
| Passini et al. | 379. CNS Delivery of Human SMN1 by Adeno-Associated Virus Is Highly Efficacious in a Mouse Model of Spinal Muscular Atrophy Type I |